SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis
A legfontosabb adatok
- Ki végzi
- Samsung Medical Center
- Hol
- Dél-Korea11 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- NCT07944066
- KCT0012093
- Állapot
- Toboroz
- Fázis
- 4. fázis
- Résztvevők
- 1182 fő, tervezett
- Kezdés
- 2026. jún. 10.
- Várható befejezés
- 2031. jún.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Enavogliflozin
- Placebo
- A regiszteradat frissítve
- 2026. november 18.
Ki vehet részt
- Életkor
- 19 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Ki vehet részt
- Able to understand the study protocol and provide written informed consent
- Adults aged 19 years or older
- Moderate or asymptomatic severe aortic stenosis, defined as all of the following:
- Aortic valve area (AVA) less than 1.5 cm2, aortic valve peak velocity (Vmax) 3 m/s or higher, or aortic valve mean pressure gradient 25 mmHg or higher
- Left ventricular ejection fraction 50% or higher
- Asymptomatic, New York Heart Association (NYHA) functional class I
Ki nem vehet részt
- Severe stenosis or regurgitation of another valve, or concomitant severe aortic regurgitation
- Use of an SGLT2 inhibitor within the previous 3 months
- Participation in another clinical trial within the previous 1 month or 5 half-lives of the investigational product
- Known hypersensitivity to SGLT2 inhibitors
- Type 1 diabetes mellitus
- Left ventricular ejection fraction below 50%
- Liver disease with AST or ALT 2 or more times the upper limit of normal, or history of hepatic encephalopathy, esophageal varices, or portosystemic shunt
- Current use of medications that may affect efficacy assessment (DPP-4 inhibitors, vitamin K, calcium supplements)
- Indication for aortic valve intervention according to current ACC/AHA or ESC/EACTS guidelines
- Symptomatic severe aortic stenosis
- Very severe aortic stenosis (aortic valve Vmax 5 m/s or higher, or mean pressure gradient 50 mmHg or higher)
- NYHA functional class II to IV
- Estimated glomerular filtration rate below 30 mL/min/1.73 m2, or on dialysis
- Pregnancy or breastfeeding
- Life expectancy below 2 years, or inability to comply with the study protocol
- Diabetic ketoacidosis
- Sexually active women of childbearing potential who do not agree to use adequate contraception during the study
Ez a vizsgálat jelenleg itt érhető el: Dél-Korea.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Aortic stenosis (AS) is the most common valvular heart disease, and no medical therapy has been shown to slow its progression; treatment is limited to surgical or transcatheter aortic valve replacement once symptoms or left ventricular dysfunction develop. Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular death and heart failure hospitalization in patients with and without diabetes, and preclinical studies show that they suppress the inflammatory (NLRP3 inflammasome), fibrotic (TGF-beta/Smad), and oxidative-stress pathways that drive valve calcification. A recent observational study reported slower AS progression in patients treated with SGLT2 inhibitors.
A teljes eredeti leírásKevesebb
SAVE-AS is a multicenter, prospective, randomized, double-blind, placebo-controlled, investigator-initiated superiority trial testing whether the SGLT2 inhibitor enavogliflozin (0.3 mg once daily) reduces the composite of all-cause death, aortic valve replacement, and hospitalization for heart failure in adults with asymptomatic moderate or severe aortic stenosis and preserved left ventricular ejection fraction (50% or higher). A total of 1,182 participants at 11 centers in the Republic of Korea will be randomized 1:1 to enavogliflozin or matching placebo, stratified by participating center and AS severity (moderate vs severe). Study treatment is given for 24 months, with follow-up visits at 2, 6, 12, 18, and 24 months and an end-of-treatment assessment at 25 months. Secondary outcomes include the individual components of the primary composite, cardiac death, echocardiographic AS severity, left ventricular mass, global longitudinal strain and ejection fraction, NT-proBNP, annual eGFR slope, and SGLT2 inhibitor-related adverse events. All clinical events are adjudicated by an independent clinical event adjudication committee, and safety is overseen by an independent data and safety monitoring board.
A vizsgálat 2 csoportja
- EnavogliflozinA vizsgált kezelés
Enavogliflozin 0.3 mg film-coated tablet orally once daily for 24 months, in addition to guideline-directed medical therapy.
- PlaceboPlacebo, összehasonlításként
Matching placebo tablet (identical in appearance) orally once daily for 24 months, in addition to guideline-directed medical therapy.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Assess the Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitor in Patients With Aortic Valve Stenosis: SAVE-AS (SGLT2i Assessment Valvular Effect in AS)
- A regiszteradat frissítve
- 2026. november 18.